Home > Dermatology > AAD 2022 > Posters > Upadacitinib: Fast and more pronounced skin improvement in AD patients

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By
Prof. Jonathan Silverberg, George Washington University School of Medicine, USA
Conference
AAD 2022
Trial
Phase 3, Heads Up
A novel analysis of the Heads Up trial revealed that a larger proportion of adult patients with moderate-to-severe atopic dermatitis (AD) achieved incrementally greater levels of skin improvement with the Janus kinase (JAK) inhibitor upadacitinib compared with patients treated with dupilumab. This effect might lead to a better quality of life in these patients. Previously, the superior efficacy of the selective JAK inhibitor upadacitinib compared with dupilumab for the treatment of moderate-to-severe AD was demonstrated in the phase 3b, randomised Heads Up study (NCT03738397) [1]. The primary study endpoint was the proportion of patients that achieved an improvement in the Eczema Area and Severity Index (EASI) by 75% from baseline at week 16. Participants were randomised 1:1 to receive either oral upadacitinib 30 mg once daily (with a placebo prefilled syringe ever...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on